PATENT

ATTORNEY DOCKET NO.: 056291-5179

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re PATENT APPLICATION of:)
NEWCOMBE et al.)) Group Art Unit:
Application No.: 10/507,169)
Filed: September 9, 2004) Examiner:
FOR: 4-IMIDAZOLYL SUBSTITUTED PYRIMIDINE DERIVATIVES WITH CDK INHIBITORY ACTIVITY) ·)
Commissioner for Patents U.S. Patent and Trademark Office Customer Service Window, Mail Stop Randolph Building 401 Dulany Street Alexandria, VA 22314	Date: February 7, 2005
Sir:	

INFORMATION DISCLOSURE STATEMENT

Attached is a Form PTO-1449 listing the enclosed foreign patent documents. Copies of the U.S. patent documents are not enclosed.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.

Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 056291-5179 and proceed to consider this IDS.

ATTORNEY DOCKET NO.: 056291-5179

Application No.: 10/507,169

Page 2

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Except for issue fees payable under 37 C.F.R. §1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,

Morgan Lewis & Bockins LLP

February 7, 2005 Date:

Morgan Lewis & Bockius LLP

Customer No. 09629

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

Tel. No.: 202-739-3000

DJB:mk

By:

Donald J. Bird

Registration No. 25,323

Tel. No.: (202) 739-5320

Fax No.: (202) 739-3001

ORM PTO-1449 (modified)						Attorney Docket No. Client				-		
ORM PTO To: U.S. [-1449 (I)epartn	modified) nent of Commerce				_			*			
Patent a	and Tra	demark Office				050	:291-5170	+	·			\dashv
·					056291-5179 Applicant: NEWCOMBE et al.							
NFORMA	TION	DISCLOSURE S	SΤΑ	TEMENT		Applicant:	TATALOONIDE OF					
BY APPLICANT Date: February 7, 2005						Appln. No.: 10/507,169						
							September 9, 200)4				
						Examiner: U		Art Unit:	Una	assigned	<u></u>	
				-								
		OCUMENTS Desument	1	Date	Name			Class	Sub		Filing	
Examiner's	1 1	Document Number	1	MM/YYYY		Family Name of First Inventor)			Class	1	Date	-t-
nitials*		Number 						-	+		(if appropri	ate
	AR	4,983,608		01/1991		Effland et al.		-	+			
	BR	5,516,775		04/1996		Zimmerma	+	+				
	CR	5,521,184		05/1996		Zimmer		 	+			
	DR	5,610,303		03/1997		Kimura et al.		+				
	ER	5,739,143		04/1998		Adams et al.			+		t	
	FR	5,859,041		01/1999		Liverton	The second of the second	I Paris	English		Translati	on
FOREIGN	I PATE	NT DOCUMENTS	. 4.	<u> </u>	ar 1 m to		- Ut Nome		Abstract		Readily	
		Document	ļ	Date	Country	Inventor/Ap	oplicant Name				Available	;
		Number	M	M/YYYY					Enclosed	No	Enclosed	N
	1		<u> </u>	1011555		+	Geisen		 	T^{T}	$T^{}$	T
	GR	2,231,765	+-	09/1998	Canada		Hubele eta I.			X	T -	1
	HR	0 135 472	+	03/1985	EPA_		Wheeler et al.		 	 		Ť
<u> </u>	IR	0 363 002	+-	04/1990	EPA_		Tomino et al.		†	T		Ţ
	JR	0 379 806 A2	+-	08/1990	EPA EDA	 	Andries et al.		†	T^-		T
	KR	0 945 443 A1	+	09/1999	EPA_	+	Ife et al.			\top	<u> </u>	T
	LR	91/18887	_	12/1991	WO_	+	Spada et al.		1	1	T^{-}	Ţ
	MR	92/20642	+	11/1992	wo_ wo	+	Zimmermann			\top	$\overline{1}$	Ţ
	NR	95/09847	_	04/1995	WO_ WO		Zimmermann					J
	OR	95/09851	+-	04/1995	WO_ WO		Zimmermann			\int		\int
<u> </u>	PR	95/09852	+-	04/1995	WO WO		Zimmermann		<u> </u>	\mathbb{I}^{-}		\int
	QR		+-	04/1995 06/1995	WO_ WO	+	Thomas et al.			\prod		
	RR		+-	02/1996	wo_ wo		Lee et al.			\perp		\int
<u> </u>	SR	96/05177 96/28427	_	02/1996	wo		Buckman et al.			\perp		
<u> </u>	TR	96/28427		12/1996	wo		Adams et al.					_
<u> </u>	UR		+	05/1997	wo		Davis et al.					
	VR WB		+	10/1997	wo		Feuerstein			1		
-	WR XR		+	10/1997	wo		Andersen et al.					
	YR		+	11/1997	wo		Berger et al.			_		_
 	ZR.	97/47618	\dagger	12/1997	wo		Liverton et al.			1_	4-	
OTUES	<u>احد</u> المعادد	ding in this order Au	itho	or. Title Pe		ime, Date, Pe	ertinent Pages, et	c.)	1			
OTHER	(Includ	•		<u>.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>	•							
	BB									<u> </u>		
	100	<u> </u>				Date Con	voidorod:					

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.